Within GBM, GPR133 expression is not related to MGMT methylation, EGFR amplification, TP53 status, molecular subtype, or even IDH status, indicating potential generalizability of its use therapeutically and even diagnostically. The gene discussed is ADGRD1; the disease is glioblastoma.